Mavenclad
cladribine · Merck Europe B.V.
AUTHORISED IN THE EUWhat Mavenclad is used for
Treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Mavenclad
- Active substance
- cladribine
- Disease area
- Multiple Sclerosis
- Medicine group
- Immunosuppressants
- ATC code
- L04AA40
- Marketing authorisation holder
- Merck Europe B.V.
- Authorised in the EU since
- 2017
Official information
In the USA
Same active substance: Mavenclad
In India
- Cladribine: 1 brand in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Mavenclad used for?
Treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features.
What is the active substance in Mavenclad?
Mavenclad contains cladribine.
Who makes Mavenclad?
The EU marketing authorisation holder is Merck Europe B.V..
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU